Cargando…

O11.4. INTERACTOME OVERLAP BETWEEN SCHIZOPHRENIA AND COGNITION

BACKGROUND: Cognitive impairments constitute a core feature of schizophrenia, and a genetic overlap between schizophrenia and cognitive functioning in healthy individuals has been identified. However, due to the high polygenicity and complex genetic architecture of both traits, overlapping biologica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koch, Elise, Rosenthale, Brin, Lundquist, Anders, Chen, Chi-Hua, Kauppi, Karolina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Oral Session: Digital Health/Methods
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233998/ http://dx.doi.org/10.1093/schbul/sbaa028.064

Ejemplares similares

O11.2. ELEVATION OF MACROPHAGE-RELATED TRANSCRIPTS IN THE MIDBRAIN IN SCHIZOPHRENIA
por: Purves-Tyson, Tertia, et al.
Publicado: (2020)

O11.5. INCREASED INFLAMMATION AND MACROPHAGE INFILTRATION IS ASSOCIATED WITH ALTERED SUBEPENDYMAL ZONE NEUROGENESIS IN SCHIZOPHRENIA BUT NOT BIPOLAR DISORDER
por: North, Hayley, et al.
Publicado: (2020)

O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS
por: Chika Onwordi, Ellis, et al.
Publicado: (2020)

O6.2. A NETWORK FOR COGNITIVE, MOTOR, AND PSYCHOPATHOLOGICAL ALTERATIONS IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Moura, Bernardo, et al.
Publicado: (2020)

O11.1. MULTIPLE GENOMIC MEASURES OF SCHIZOPHRENIA RISK ARE RELATED TO CORTICAL THICKNESS IN TYPICALLY DEVELOPING YOUTH AND YOUNG ADULTS
por: Jalbrzikowski, Maria, et al.
Publicado: (2020)

O6.3. ASSOCIATIONS BETWEEN COGNITIVE FUNCTION AND CORTICAL LEVELS OF GLUTAMATE AND GABA IN ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS
por: Bojesen, Kirsten, et al.
Publicado: (2020)

O4.1. AEROBIC EXERCISE DOSE DETERMINES THE COGNITIVE GAIN IN FIRST-EPISODE SCHIZOPHRENIA, SO HOW DO WE ENCOURAGE SUFFICIENT EXERCISE?
por: Nuechterlein, Keith, et al.
Publicado: (2020)

Sex-specific effects of polygenic risk for schizophrenia on lifespan cognitive functioning in healthy individuals
por: Koch, Elise, et al.
Publicado: (2021)

O2.4. FUNCTIONAL CONNECTOME-WIDE ASSOCIATIONS OF SCHIZOPHRENIA POLYGENIC RISK
por: Cao, Hengyi, et al.
Publicado: (2020)

O4.6. REAL-TIME FMRI NEUROFEEDBACK FOR TREATMENT REFRACTORY HALLUCINATIONS IN SCHIZOPHRENIA
Publicado: (2020)

O2.1. LOCAL AND LONG-RANGE CONNECTIVITY PATTERNS OF AUDITORY PERCEPTUAL DISTURBANCE IN SCHIZOPHRENIA
por: Hare, Stephanie, et al.
Publicado: (2020)

O5.5. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: MULTI-MODAL PET AND FMRI FINDINGS
por: Howes, Oliver, et al.
Publicado: (2020)

O1.4. HOW THE MOST CITED RESEARCH ARTICLES ABOUT SCHIZOPHRENIA IN 2018 DEPICT THE DISEASE?
por: Tonsig, Gabriela, et al.
Publicado: (2020)

O5.1. STRIATAL DOPAMINE AND REDUCED REWARD PREDICTION ERROR SIGNALING IN UNMEDICATED SCHIZOPHRENIA PATIENTS
por: Katthagen, Teresa, et al.
Publicado: (2020)

Polygenic Risk for Schizophrenia Has Sex-Specific Effects on Brain Activity during Memory Processing in Healthy Individuals
por: Koch, Elise, et al.
Publicado: (2022)

O9.7. TECHNOLOGY ASSISTED RELAPSE PREVENTION PROGRAM REDUCES HOSPITALIZATION IN SCHIZOPHRENIA PATIENTS AT HIGH RISK FOR RELAPSE
por: Schooler, Nina, et al.
Publicado: (2020)

O3.1. CLUSTER ANALYSIS FINDS THREE CLINICALLY-RELEVANT SUBGROUPS OF TRAIT EMOTIONAL EXPERIENCE IN SCHIZOPHRENIA OUTPATIENTS
por: Cowan, Henry, et al.
Publicado: (2020)

O4.2. THE PREVENTION OF RELAPSE AND HOSPITALIZATION IN FIRST EPISODE AND EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE PRELAPSE TRIAL
por: Kane, John, et al.
Publicado: (2020)

O2.5. CORTICAL PATTERNING OF ABNORMAL MORPHOMETRIC SIMILARITY IN PSYCHOSIS IS ASSOCIATED WITH BRAIN EXPRESSION OF SCHIZOPHRENIA-RELATED GENES
Publicado: (2020)

O1.5. CLUSTERING-BASED BEHAVIOURAL PHENOTYPES OF INTRINSIC MOTIVATION IN SCHIZOPHRENIA DETERMINED USING OBJECTIVELY QUANTIFIED REAL-WORLD PERFORMANCE
por: Siddiqui, Ishraq, et al.
Publicado: (2020)

O8.1. ASSOCIATION BETWEEN GENETIC AND ENVIRONMENTAL RISK FOR SCHIZOPHRENIA DURING UPBRINGING: FINDINGS FROM A LONGITUDINAL COHORT STUDY
por: Newbury, Joanne, et al.
Publicado: (2020)

O1.6. AFFECTIVE DETERMINANTS OF LIFE-SPACE THROUGH GPS AND ECOLOGICAL MOMENTARY ASSESSMENT IN SCHIZOPHRENIA: WHAT GETS PEOPLE OUT OF THE HOUSE?
por: Parrish, Emma, et al.
Publicado: (2020)

O4.3. SHARED AND DIFFERENTIAL NEUROCOGNITIVE EFFECTS COMPARING HIGH-INTENSITY INTERVAL TRAINING AND ACTIVE VIDEO-GAMING IN SCHIZOPHRENIA – RESULTS FROM AN RCT
por: Bang-Kittilsen, Gry, et al.
Publicado: (2020)

O3.2. ROBOT-INDUCED MILD HALLUCINATIONS AND PASSIVITY EXPERIENCES IN INDIVIDUALS WITH THE 22Q11.2 DELETION SYNDROME
por: Potheegadoo, Jevita, et al.
Publicado: (2020)

O11.6. THE ROLE OF SERUM GLUTAMATE AND ASPARTATE AS MARKERS FOR CLOZAPINE RESPONSE AND IN THE MECHANISM OF ACTION – DATA FROM HUMAN AND ANIMAL MODEL STUDIES
Publicado: (2020)

O1.1. ETRo: EVALUATION OF THE TREATMENT APPROACH “ROBIN” (STANDARDIZED MANUAL AND SMARTPHONE APP) FOR ADOLESCENTS WITH CLINICAL HIGH RISK FOR DEVELOPING A PSYCHOTIC DISORDER
por: Traber-Walker, Nina, et al.
Publicado: (2020)

O4.5. LONG TERM EFFECTS OF EARLY INTERVENTION SERVICES FOR FIRST EPISODE PSYCHOSIS: OUTCOMES OVER FIVE YEARS FROM THE RECOVERY AFTER A 1ST EPISODE OF SCHIZOPHRENIA-EARLY TREATMENT PROGRAM (RAISE-ETP)
por: Robinson, Delbert, et al.
Publicado: (2020)

O6.1. COGNITIVE CONTROL DIFFERENCES BETWEEN TREATMENT RESPONSIVE AND TREATMENT RESISTANT FIRST-EPISODE PSYCHOSIS PATIENTS
Publicado: (2020)

O7.3. EXPLORING COMORBIDITY BETWEEN MENTAL DISORDERS AND GENERAL MEDICAL CONDITIONS
por: Momen, Natalie, et al.
Publicado: (2020)

S163: POLYSOME INTERACTOME IN RPS14-DEFICIENT CELLS REVEALS THE INVOLVEMENT OF THE MRNA DECAY MACHINERY IN TRANSLATION SELECTIVITY.
por: Tuerdi, Zubaidan, et al.
Publicado: (2023)

S114: OUTCOME OF OLDER PATIENTS (>55 YRS) WITH NEWLY DIAGNOSED PH/BCR:ABL POSITIVE ALL PROSPECTIVELY TREATED ACCORDING TO PEDIATRIC-BASED, AGE-ADAPTED GMALL PROTOCOLS
por: Lang, Fabian, et al.
Publicado: (2023)

O9.4. RELATIONSHIPS BETWEEN AGE AT ONSET OF PSYCHOTIC SYMPTOMS AND POOR RESPONSE TO ANTIPSYCHOTICS IN A SAMPLE OF TRS/NON-TRS PATIENTS
por: Iasevoli, Felice, et al.
Publicado: (2020)

O7.1. ASSOCIATION BETWEEN PATTERNS OF COMORBID MENTAL DISORDERS AND MORTALITY-RELATED ESTIMATES. A NATIONWIDE, REGISTER-BASED COHORT STUDY BASED ON 7.5 MILLION INDIVIDUALS LIVING IN DENMARK
por: Plana-Ripoll, Oleguer, et al.
Publicado: (2020)

O3.6. PREVALENCE OF AND RECOVERY FROM COMMON MENTAL DISORDERS INCLUDING PSYCHOTIC EXPERIENCES
por: Perez, Jesus, et al.
Publicado: (2020)

O7.5. STANDARDIZED MORTALITY RATIOS IN EARLY- AND ADULT ONSET FOR THREE DISORDERS
por: Lammers Vernal, Ditte, et al.
Publicado: (2020)

O10.5. CLINICAL HIGH RISK (CHR) CRITERIA IN CHILDREN AND ADOLESCENTS NOT SUSPECTED TO DEVELOP PSYCHOSIS: NO TRANSDIAGNOSTIC SEVERITY MARKER OF MENTAL HEALTH PROBLEMS
por: Schultze-Lutter, Frauke, et al.
Publicado: (2020)

O5.6. ADVANCED DIFFUSION IMAGING IN PSYCHOSIS RISK: A CROSS-SECTIONAL AND LONGITUDINAL STUDY OF WHITE MATTER DEVELOPMENT
por: Di Biase, Maria, et al.
Publicado: (2020)

O3.5. EARLY TRAJECTORIES OF POSITIVE SYMPTOMS REMISSION IN FIRST EPISODE-PSYCHOSIS: A 2-YEAR FOLLOW-UP STUDY
por: Percie du Sert, Olivier, et al.
Publicado: (2020)

O2.2. EVALUATION OF THE RELATIONSHIP BETWEEN GLUTAMATE AND BRAIN CONNECTIVITY IN ANTIPSYCHOTIC-NAïVE FIRST EPISODE PATIENTS – A COMBINED MAGNETIC RESONANCE SPECTROSCOPY AND RESTING STATE FUNCTIONAL CONNECTIVITY MRI STUDY
por: Maximo, Jose, et al.
Publicado: (2020)

O6.4. ASSOCIATION BETWEEN CLUSTERS OF FORMAL THOUGHT DISORDERS SEVERITY AND NEUROCOGNITIVE AND FUNCTIONAL OUTCOME INDICES IN THE EARLY STAGES OF PSYCHOSIS – RESULTS FROM THE PRONIA COHORT
por: Öztürk, Ömer Faruk, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nkdnmc46tctl2efplbbvqjv3ve